MBOT vs. NXGL, GCTK, PETV, MHUA, BTCY, TTOO, PAVM, SSKN, AKLI, and PSTV
Should you be buying Microbot Medical stock or one of its competitors? The main competitors of Microbot Medical include NEXGEL (NXGL), GlucoTrack (GCTK), PetVivo (PETV), Meihua International Medical Technologies (MHUA), Biotricity (BTCY), T2 Biosystems (TTOO), PAVmed (PAVM), STRATA Skin Sciences (SSKN), Akili (AKLI), and Plus Therapeutics (PSTV). These companies are all part of the "surgical & medical instruments" industry.
Microbot Medical (NASDAQ:MBOT) and NEXGEL (NASDAQ:NXGL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk.
Microbot Medical received 345 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 70.61% of users gave Microbot Medical an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.
Microbot Medical presently has a consensus target price of $7.00, suggesting a potential upside of 695.36%. Given Microbot Medical's higher possible upside, equities research analysts clearly believe Microbot Medical is more favorable than NEXGEL.
16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 2.2% of NEXGEL shares are owned by institutional investors. 10.6% of Microbot Medical shares are owned by company insiders. Comparatively, 27.2% of NEXGEL shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Microbot Medical had 3 more articles in the media than NEXGEL. MarketBeat recorded 5 mentions for Microbot Medical and 2 mentions for NEXGEL. Microbot Medical's average media sentiment score of 0.40 beat NEXGEL's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media.
Microbot Medical has a net margin of 0.00% compared to NEXGEL's net margin of -77.19%. NEXGEL's return on equity of -49.49% beat Microbot Medical's return on equity.
Microbot Medical has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, NEXGEL has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
NEXGEL has higher revenue and earnings than Microbot Medical. NEXGEL is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Microbot Medical beats NEXGEL on 10 of the 16 factors compared between the two stocks.
Get Microbot Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Microbot Medical Competitors List
Related Companies and Tools
